Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (524)	4/18/1999 6:01:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

A brief mining expedition... and did not want to throw the urls away. holidaylectures.org bioinfo.weizmann.ac.il bioinfo.weizmann.ac.il cbweb.med.harvard.edu --this last url has a slide show on p53, that one caught my eye because I recently decided to buy 1000 shares of Onyx. You may want to look at the slides at work, or some place where you have decent 'bandwidth'. NF-ATc proteins play a key regulatory role in the immune response and in cardiac hypertrophy. U.S. Patent 5,837,840, "NF-AT Polypeptides and Polynucleotides," was issued to Stanford University on November 17, 1998. ARIAD is the exclusive worldwide licensee. I am just parking urls mainly, as Rick likes to say. Lately I have been reading more and chatting less on SI, and I certainly don't have anything to say about Ariad stock, I'm at a loss;-) But I still like to surf around, just to see what comes up in my net. Note, there are only a few good posts on the yahoo board in the last month or so, mainly from Pirkkal. If somebody would like to post specifically on the relationship of Mr. Crabtree to Ariad (parking lot data is sometimes useful) that would be nice. Seems like the company has been awfully quiet of late--has anybody received the annual report in the mail? I have not received anything since last summer's letter to shareholders. How aboud Edgar, anything new there? --Mike